Cometriq Attack on Immune Cells May Explain Earlier Failure in Prostate Cancer Trial

Cometriq Attack on Immune Cells May Explain Earlier Failure in Prostate Cancer Trial
A study of Cometriq (cabozantinib) in mice with aggressive prostate cancer may explain why a previous clinical trial of the drug failed to treat human prostate cancer. Researchers demonstrated that Cometriq acts by engaging particular cells of the innate immune system — cells that wiped out aggressive tumors in mice in a matter of days.

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Tagged , , , , .

Magdalena holds an MSc in Pharmaceutical Bioscience and an interdisciplinary PhD merging the fields of psychiatry, immunology and neuropharmacology. Her previous research focused on metabolic and immunologic changes in psychotic disorders. She is now focusing on science writing, allowing her to culture her passion for medical science and human health.

Leave a Comment

Your email address will not be published. Required fields are marked *